{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-000742","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2025-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.209145+00:00","generated_at":"2026-05-24T04:58:37.313285+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Evofem signs manufacturing deal to cut PHEXXI cost ~55-60%; extends merger close to Sept 2025 with $1.5M investment","bullets":["Windtree to manufacture PHEXXI; Evofem expects COGS reduction of 55-60%.","No cost to Evofem for tech transfer; Windtree engaged a manufacturer.","Fifth Amendment extends merger consummation date to Sept 30, 2025.","Aditxt must invest $1.5M by April 7, 2025 via F-1 preferred or notes.","Evofem to use best efforts to hold shareholder meeting by Sept 26, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-000742","json":"https://secwatch.observer/filing/0001641172-25-000742.json","markdown":"https://secwatch.observer/filing/0001641172-25-000742.md","text":"https://secwatch.observer/filing/0001641172-25-000742.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000164117225000742/0001641172-25-000742-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000164117225000742/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:58:37.313285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}